

The Future of Checkpoint Inhibition in Cancer: Are We About to Challenge the Standard of Care Across Multiple Solid Tumors (Breast, Gastrointestinal, and Genitourinary Cancers)?

Sunday, 10 September 2017

13:00 – 14:30

Satellite Symposium
Sponsored by MSD

IFEMA, Feria de Madrid
Cordoba Auditorium Hall 4
Madrid, Spain

Chair: Javier Cortes (Spain)

CHAIR

Javier Cortes

Head, Breast Cancer and Gynecological
Tumours
Ramón y Cajal University Hospital,
Oncology Department
Madrid, Spain

FACULTY

Joaquim Bellmunt

Associate Professor
Harvard Medical School
Dana-Farber/Brigham and Women's
Cancer Center
Boston, Massachusetts, USA

Axel Grothey

Medical Oncology and Hematology/
Oncology
Mayo Clinic
Rochester, Minnesota, USA

Educational Objectives

- Provide a future perspective on potential integration of anti-PD-1 therapy, as monotherapy and in combination with other treatments, in routine clinical practice. It will also review key findings on use of these agents that may optimize future use in patients and potentially improve future treatment success
- Establish a better understanding of future treatment algorithms by patient type
- Provide an understanding of emerging therapeutic options for breast, gastrointestinal, and genitourinary cancers

AGENDA

13:00 – 13:05	Welcome and Introduction	Javier Cortes
13:05 – 13:15	Opening Remarks: Tumor Immunology and the Role of Checkpoint Inhibitors	Javier Cortes
13:15 – 13:35	The Potential Role of Checkpoint Inhibitors in the Treatment of Gastrointestinal (GI) Cancers – What Is Promising and What Questions Need to Be Addressed?	Axel Grothey
13:35 – 13:55	Immunotherapy in Genitourinary (GU) Cancers: Results and Ongoing Clinical Trials	Joaquim Bellmunt
13:55 – 14:15	The Emerging Potential of Checkpoint Inhibitors in the Treatment of Breast Cancers	Javier Cortes
14:15 – 14:25	Q&A	Faculty
14:25 – 14:30	Closing Remarks	Javier Cortes